ASTRAZENECA BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
AstraZeneca's product portfolio sits at the intersection of biotech innovation and global scale-some oncology and rare-disease franchises look like Stars, mature CV and respiratory treatments behave as Cash Cows, while certain older respiratory lines risk slipping toward Dogs unless refreshed. This snapshot hints at strategic reallocation: invest in high-growth biologics, harvest steady cash-generators, and divest or reposition underperformers. Purchase the full BCG Matrix for quadrant-level placements, actionable recommendations, and downloadable Word/Excel files to drive investment and portfolio decisions.
Stars
Imfinzi (Durvalumab)
Imfinzi (Durvalumab) is a Stars asset for Company Name, surging 28% to $6.06 billion in 2025 revenue and anchoring the oncology portfolio.
Growth is driven by expansion into early-stage lung, gastric, and bladder indications where Imfinzi holds leading market share versus PD-1/PD-L1 rivals.
As high-growth, high-share, Imfinzi needs sustained R&D and trial spend-Company Name must keep investment to defend share and delay biosimilar/PD-1 competition.
Enhertu (Trastuzumab Deruxtecan)
Enhertu (trastuzumab deruxtecan) is AstraZeneca's crown‑jewel ADC from the Daiichi Sankyo deal, growing 40% to $2.78 billion in 2025 and redefining HER2‑low breast cancer to capture a hard‑to‑reach market segment.
It stays a Star in AstraZeneca's BCG matrix: high revenue and growth, but intensive capital is tied up in an expansive, multi‑tumor clinical trial program that sustains its high investment needs.
Ultomiris (Ravulizumab)
Ultomiris (ravulizumab) succeeded Soliris, migrating most rare-disease patients and driving sales up 16% to $1.27 billion in Q4 2025, cementing its Star status in AstraZeneca's BCG Matrix.
It holds a near-monopoly in the C5 inhibitor class for paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG), aided by a more convenient dosing interval than Soliris.
Ongoing expansion into pediatric HSCT-TMA and other indications underpins high growth potential, but requires significant global launch investment and commercial support.
Calquence (Acalabrutinib)
Calquence (acalabrutinib) grew 17% in 2025 to $3.13 billion, becoming AstraZeneca's preferred frontline BTK inhibitor for chronic lymphocytic leukemia due to a superior safety profile that is taking share from Imbruvica.
Revenue strength and profitability mark it a high-growth leader, but costly head-to-head trials and commercial placement spend keep it in the Star quadrant.
- 2025 revenue: $3.13 billion (↑17%)
- Frontline CLL share gains vs Imbruvica
- Better safety profile drives adoption
- High trial/commercial costs maintain Star status
Farxiga (Dapagliflozin)
Farxiga (dapagliflozin) is a Star for AstraZeneca: 2025 sales hit $8.41 billion, led by expansion from diabetes into heart failure and chronic kidney disease, keeping growth in the high single digits.
Its ongoing uptake in new patient populations sustains premium pricing and volume, but patent cliffs in the late 2020s make it crucial to maximize market share before generic entry.
- 2025 sales: $8.41 billion
- Growth: high single digits (2025)
- Drivers: heart failure, CKD approvals/label expansions
- Risk: patent expiries late 2020s - urgent share defense
High‑growth stars (Imfinzi, Enhertu, Calquence, Ultomiris, Farxiga) face costly defenses
Stars: Imfinzi $6.06B (2025, +28%); Enhertu $2.78B (+40%); Calquence $3.13B (+17%); Ultomiris $1.27B (Q4 2025, +16%); Farxiga $8.41B (2025). High share/high growth; require continued R&D, trials, and commercial spend to defend against competition and upcoming patent risks.
| Asset | 2025 Rev | Growth | Key Risk |
|---|---|---|---|
| Imfinzi | $6.06B | +28% | PD‑1/PD‑L1 competition |
| Enhertu | $2.78B | +40% | High trial spend |
| Calquence | $3.13B | +17% | Head‑to‑head costs |
| Ultomiris | $1.27B | +16% (Q4) | Launch investment |
| Farxiga | $8.41B | High single digits | Patent cliffs |
What is included in the product
Detailed Word Document
Concise BCG review of AstraZeneca's portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, divest guidance.
Customizable Excel Spreadsheet
One-page overview placing each AstraZeneca business unit in a quadrant, simplifying strategic decisions for busy executives.
Cash Cows
Tagrisso (Osimertinib)
Tagrisso (osimertinib) is AstraZeneca's top-selling oncology product, delivering $7.25 billion in 2025 revenue and acting as a classic cash cow in the BCG matrix.
Growth remains a healthy 10% year-over-year, but market maturity and dominant EGFR-mutant lung cancer share cut promotional needs versus newer launches.
The drug generates large, predictable cash flow that helps fund AstraZeneca's R&D program, which exceeds $13 billion annually.
Lynparza (Olaparib)
Lynparza (olaparib), a PARP inhibitor co-marketed with Merck, generated $3.28 billion in 2025, growing 6% year-over-year and remaining the class leader.
Its mature position in ovarian and breast cancer is defended by extensive clinical data, driving sustained uptake and prescribing loyalty.
Classified as a Cash Cow for AstraZeneca, Lynparza delivers high margins and predictable cash flow with little need for new capital investment.
Symbicort (Budesonide/Formoterol)
AstraZeneca's Symbicort (budesonide/formoterol) remained a cash cow, generating $2.88 billion in 2024/2025 and sustaining ~25-30% share in mature asthma/COPD markets despite generics.
Strong brand loyalty and recognition as a cost‑effective standard of care keep prescribing high, so marketing spend is minimal and net margins stay robust.
Free cash flow from Symbicort is being harvested to fund Stars like Tezspire (2025 revenue: $3.1 billion), supporting R&D and commercial expansion.
Soliris (Eculizumab)
Soliris (eculizumab), once AstraZeneca's star, is a fading Cash Cow: it generated $2.59 billion in 2025, but sales fell 26% in the final quarter as patients migrated to Ultomiris.
It still delivers high-margin cash in select markets and legacy indications with essentially zero R&D spend; AZ is milking the asset ahead of biosimilar erosion.
- 2025 sales $2.59B; Q4 -26%
- High margins, no incremental R&D
- Value concentrated in older indications/markets
- Facing biosimilar and Ultomiris substitution pressure
Brilinta (Ticagrelor)
Brilinta (ticagrelor) produced $1.33 billion in 2024/2025 sales, acting as AstraZeneca's cash cow in the antiplatelet segment with low growth but predictable hospital demand.
Pressure from generic clopidogrel and price-sensitive markets limits expansion, yet entrenched guideline use keeps steady margins to fund AZ's shift into high-growth cardiometabolic R&D.
- 2024/25 sales: $1.33B
- Role: steady hospital revenue, low growth
- Threat: cheaper generics; Opportunity: funding R&D
AZ's $17.3B cash-cow core funds $13B+ R&D - Tagrisso, Lynparza lead; Soliris slides
Tagrisso $7.25B (2025, +10%); Lynparza $3.28B (+6%); Symbicort $2.88B; Soliris $2.59B (2025, Q4 -26%); Brilinta $1.33B - all high-margin, low-growth cash cows funding AZ's R&D ($13B+).
| Product | 2025 Sales | Growth |
|---|---|---|
| Tagrisso | $7.25B | +10% |
| Lynparza | $3.28B | +6% |
| Symbicort | $2.88B | ~0% |
| Soliris | $2.59B | -26% Q4 |
| Brilinta | $1.33B | ~0% |
Delivered as Shown
AstraZeneca BCG Matrix
The file you're previewing on this page is the final AstraZeneca BCG Matrix you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, presentation-ready strategic analysis tailored for pharma portfolio decisions.
This preview is the exact same document you'll download post-purchase, built with market-backed metrics and clear visuals so you can immediately use it in board decks, investor updates, or internal strategy sessions.
Upon purchase you'll get the full editable file delivered to your inbox-no surprises, no revisions required-ready for printing, customization, or sharing with stakeholders.
What you see here is the real AstraZeneca BCG Matrix report crafted by strategy experts, designed for clarity and immediate application in product lifecycle and resource-allocation planning.
ASTRAZENECA BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
AstraZeneca's product portfolio sits at the intersection of biotech innovation and global scale-some oncology and rare-disease franchises look like Stars, mature CV and respiratory treatments behave as Cash Cows, while certain older respiratory lines risk slipping toward Dogs unless refreshed. This snapshot hints at strategic reallocation: invest in high-growth biologics, harvest steady cash-generators, and divest or reposition underperformers. Purchase the full BCG Matrix for quadrant-level placements, actionable recommendations, and downloadable Word/Excel files to drive investment and portfolio decisions.
Stars
Imfinzi (Durvalumab)
Imfinzi (Durvalumab) is a Stars asset for Company Name, surging 28% to $6.06 billion in 2025 revenue and anchoring the oncology portfolio.
Growth is driven by expansion into early-stage lung, gastric, and bladder indications where Imfinzi holds leading market share versus PD-1/PD-L1 rivals.
As high-growth, high-share, Imfinzi needs sustained R&D and trial spend-Company Name must keep investment to defend share and delay biosimilar/PD-1 competition.
Enhertu (Trastuzumab Deruxtecan)
Enhertu (trastuzumab deruxtecan) is AstraZeneca's crown‑jewel ADC from the Daiichi Sankyo deal, growing 40% to $2.78 billion in 2025 and redefining HER2‑low breast cancer to capture a hard‑to‑reach market segment.
It stays a Star in AstraZeneca's BCG matrix: high revenue and growth, but intensive capital is tied up in an expansive, multi‑tumor clinical trial program that sustains its high investment needs.
Ultomiris (Ravulizumab)
Ultomiris (ravulizumab) succeeded Soliris, migrating most rare-disease patients and driving sales up 16% to $1.27 billion in Q4 2025, cementing its Star status in AstraZeneca's BCG Matrix.
It holds a near-monopoly in the C5 inhibitor class for paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG), aided by a more convenient dosing interval than Soliris.
Ongoing expansion into pediatric HSCT-TMA and other indications underpins high growth potential, but requires significant global launch investment and commercial support.
Calquence (Acalabrutinib)
Calquence (acalabrutinib) grew 17% in 2025 to $3.13 billion, becoming AstraZeneca's preferred frontline BTK inhibitor for chronic lymphocytic leukemia due to a superior safety profile that is taking share from Imbruvica.
Revenue strength and profitability mark it a high-growth leader, but costly head-to-head trials and commercial placement spend keep it in the Star quadrant.
- 2025 revenue: $3.13 billion (↑17%)
- Frontline CLL share gains vs Imbruvica
- Better safety profile drives adoption
- High trial/commercial costs maintain Star status
Farxiga (Dapagliflozin)
Farxiga (dapagliflozin) is a Star for AstraZeneca: 2025 sales hit $8.41 billion, led by expansion from diabetes into heart failure and chronic kidney disease, keeping growth in the high single digits.
Its ongoing uptake in new patient populations sustains premium pricing and volume, but patent cliffs in the late 2020s make it crucial to maximize market share before generic entry.
- 2025 sales: $8.41 billion
- Growth: high single digits (2025)
- Drivers: heart failure, CKD approvals/label expansions
- Risk: patent expiries late 2020s - urgent share defense
High‑growth stars (Imfinzi, Enhertu, Calquence, Ultomiris, Farxiga) face costly defenses
Stars: Imfinzi $6.06B (2025, +28%); Enhertu $2.78B (+40%); Calquence $3.13B (+17%); Ultomiris $1.27B (Q4 2025, +16%); Farxiga $8.41B (2025). High share/high growth; require continued R&D, trials, and commercial spend to defend against competition and upcoming patent risks.
| Asset | 2025 Rev | Growth | Key Risk |
|---|---|---|---|
| Imfinzi | $6.06B | +28% | PD‑1/PD‑L1 competition |
| Enhertu | $2.78B | +40% | High trial spend |
| Calquence | $3.13B | +17% | Head‑to‑head costs |
| Ultomiris | $1.27B | +16% (Q4) | Launch investment |
| Farxiga | $8.41B | High single digits | Patent cliffs |
What is included in the product
Detailed Word Document
Concise BCG review of AstraZeneca's portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, divest guidance.
Customizable Excel Spreadsheet
One-page overview placing each AstraZeneca business unit in a quadrant, simplifying strategic decisions for busy executives.
Cash Cows
Tagrisso (Osimertinib)
Tagrisso (osimertinib) is AstraZeneca's top-selling oncology product, delivering $7.25 billion in 2025 revenue and acting as a classic cash cow in the BCG matrix.
Growth remains a healthy 10% year-over-year, but market maturity and dominant EGFR-mutant lung cancer share cut promotional needs versus newer launches.
The drug generates large, predictable cash flow that helps fund AstraZeneca's R&D program, which exceeds $13 billion annually.
Lynparza (Olaparib)
Lynparza (olaparib), a PARP inhibitor co-marketed with Merck, generated $3.28 billion in 2025, growing 6% year-over-year and remaining the class leader.
Its mature position in ovarian and breast cancer is defended by extensive clinical data, driving sustained uptake and prescribing loyalty.
Classified as a Cash Cow for AstraZeneca, Lynparza delivers high margins and predictable cash flow with little need for new capital investment.
Symbicort (Budesonide/Formoterol)
AstraZeneca's Symbicort (budesonide/formoterol) remained a cash cow, generating $2.88 billion in 2024/2025 and sustaining ~25-30% share in mature asthma/COPD markets despite generics.
Strong brand loyalty and recognition as a cost‑effective standard of care keep prescribing high, so marketing spend is minimal and net margins stay robust.
Free cash flow from Symbicort is being harvested to fund Stars like Tezspire (2025 revenue: $3.1 billion), supporting R&D and commercial expansion.
Soliris (Eculizumab)
Soliris (eculizumab), once AstraZeneca's star, is a fading Cash Cow: it generated $2.59 billion in 2025, but sales fell 26% in the final quarter as patients migrated to Ultomiris.
It still delivers high-margin cash in select markets and legacy indications with essentially zero R&D spend; AZ is milking the asset ahead of biosimilar erosion.
- 2025 sales $2.59B; Q4 -26%
- High margins, no incremental R&D
- Value concentrated in older indications/markets
- Facing biosimilar and Ultomiris substitution pressure
Brilinta (Ticagrelor)
Brilinta (ticagrelor) produced $1.33 billion in 2024/2025 sales, acting as AstraZeneca's cash cow in the antiplatelet segment with low growth but predictable hospital demand.
Pressure from generic clopidogrel and price-sensitive markets limits expansion, yet entrenched guideline use keeps steady margins to fund AZ's shift into high-growth cardiometabolic R&D.
- 2024/25 sales: $1.33B
- Role: steady hospital revenue, low growth
- Threat: cheaper generics; Opportunity: funding R&D
AZ's $17.3B cash-cow core funds $13B+ R&D - Tagrisso, Lynparza lead; Soliris slides
Tagrisso $7.25B (2025, +10%); Lynparza $3.28B (+6%); Symbicort $2.88B; Soliris $2.59B (2025, Q4 -26%); Brilinta $1.33B - all high-margin, low-growth cash cows funding AZ's R&D ($13B+).
| Product | 2025 Sales | Growth |
|---|---|---|
| Tagrisso | $7.25B | +10% |
| Lynparza | $3.28B | +6% |
| Symbicort | $2.88B | ~0% |
| Soliris | $2.59B | -26% Q4 |
| Brilinta | $1.33B | ~0% |
Delivered as Shown
AstraZeneca BCG Matrix
The file you're previewing on this page is the final AstraZeneca BCG Matrix you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, presentation-ready strategic analysis tailored for pharma portfolio decisions.
This preview is the exact same document you'll download post-purchase, built with market-backed metrics and clear visuals so you can immediately use it in board decks, investor updates, or internal strategy sessions.
Upon purchase you'll get the full editable file delivered to your inbox-no surprises, no revisions required-ready for printing, customization, or sharing with stakeholders.
What you see here is the real AstraZeneca BCG Matrix report crafted by strategy experts, designed for clarity and immediate application in product lifecycle and resource-allocation planning.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
AstraZeneca's product portfolio sits at the intersection of biotech innovation and global scale-some oncology and rare-disease franchises look like Stars, mature CV and respiratory treatments behave as Cash Cows, while certain older respiratory lines risk slipping toward Dogs unless refreshed. This snapshot hints at strategic reallocation: invest in high-growth biologics, harvest steady cash-generators, and divest or reposition underperformers. Purchase the full BCG Matrix for quadrant-level placements, actionable recommendations, and downloadable Word/Excel files to drive investment and portfolio decisions.
Stars
Imfinzi (Durvalumab)
Imfinzi (Durvalumab) is a Stars asset for Company Name, surging 28% to $6.06 billion in 2025 revenue and anchoring the oncology portfolio.
Growth is driven by expansion into early-stage lung, gastric, and bladder indications where Imfinzi holds leading market share versus PD-1/PD-L1 rivals.
As high-growth, high-share, Imfinzi needs sustained R&D and trial spend-Company Name must keep investment to defend share and delay biosimilar/PD-1 competition.
Enhertu (Trastuzumab Deruxtecan)
Enhertu (trastuzumab deruxtecan) is AstraZeneca's crown‑jewel ADC from the Daiichi Sankyo deal, growing 40% to $2.78 billion in 2025 and redefining HER2‑low breast cancer to capture a hard‑to‑reach market segment.
It stays a Star in AstraZeneca's BCG matrix: high revenue and growth, but intensive capital is tied up in an expansive, multi‑tumor clinical trial program that sustains its high investment needs.
Ultomiris (Ravulizumab)
Ultomiris (ravulizumab) succeeded Soliris, migrating most rare-disease patients and driving sales up 16% to $1.27 billion in Q4 2025, cementing its Star status in AstraZeneca's BCG Matrix.
It holds a near-monopoly in the C5 inhibitor class for paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG), aided by a more convenient dosing interval than Soliris.
Ongoing expansion into pediatric HSCT-TMA and other indications underpins high growth potential, but requires significant global launch investment and commercial support.
Calquence (Acalabrutinib)
Calquence (acalabrutinib) grew 17% in 2025 to $3.13 billion, becoming AstraZeneca's preferred frontline BTK inhibitor for chronic lymphocytic leukemia due to a superior safety profile that is taking share from Imbruvica.
Revenue strength and profitability mark it a high-growth leader, but costly head-to-head trials and commercial placement spend keep it in the Star quadrant.
- 2025 revenue: $3.13 billion (↑17%)
- Frontline CLL share gains vs Imbruvica
- Better safety profile drives adoption
- High trial/commercial costs maintain Star status
Farxiga (Dapagliflozin)
Farxiga (dapagliflozin) is a Star for AstraZeneca: 2025 sales hit $8.41 billion, led by expansion from diabetes into heart failure and chronic kidney disease, keeping growth in the high single digits.
Its ongoing uptake in new patient populations sustains premium pricing and volume, but patent cliffs in the late 2020s make it crucial to maximize market share before generic entry.
- 2025 sales: $8.41 billion
- Growth: high single digits (2025)
- Drivers: heart failure, CKD approvals/label expansions
- Risk: patent expiries late 2020s - urgent share defense
High‑growth stars (Imfinzi, Enhertu, Calquence, Ultomiris, Farxiga) face costly defenses
Stars: Imfinzi $6.06B (2025, +28%); Enhertu $2.78B (+40%); Calquence $3.13B (+17%); Ultomiris $1.27B (Q4 2025, +16%); Farxiga $8.41B (2025). High share/high growth; require continued R&D, trials, and commercial spend to defend against competition and upcoming patent risks.
| Asset | 2025 Rev | Growth | Key Risk |
|---|---|---|---|
| Imfinzi | $6.06B | +28% | PD‑1/PD‑L1 competition |
| Enhertu | $2.78B | +40% | High trial spend |
| Calquence | $3.13B | +17% | Head‑to‑head costs |
| Ultomiris | $1.27B | +16% (Q4) | Launch investment |
| Farxiga | $8.41B | High single digits | Patent cliffs |
What is included in the product
Detailed Word Document
Concise BCG review of AstraZeneca's portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, divest guidance.
Customizable Excel Spreadsheet
One-page overview placing each AstraZeneca business unit in a quadrant, simplifying strategic decisions for busy executives.
Cash Cows
Tagrisso (Osimertinib)
Tagrisso (osimertinib) is AstraZeneca's top-selling oncology product, delivering $7.25 billion in 2025 revenue and acting as a classic cash cow in the BCG matrix.
Growth remains a healthy 10% year-over-year, but market maturity and dominant EGFR-mutant lung cancer share cut promotional needs versus newer launches.
The drug generates large, predictable cash flow that helps fund AstraZeneca's R&D program, which exceeds $13 billion annually.
Lynparza (Olaparib)
Lynparza (olaparib), a PARP inhibitor co-marketed with Merck, generated $3.28 billion in 2025, growing 6% year-over-year and remaining the class leader.
Its mature position in ovarian and breast cancer is defended by extensive clinical data, driving sustained uptake and prescribing loyalty.
Classified as a Cash Cow for AstraZeneca, Lynparza delivers high margins and predictable cash flow with little need for new capital investment.
Symbicort (Budesonide/Formoterol)
AstraZeneca's Symbicort (budesonide/formoterol) remained a cash cow, generating $2.88 billion in 2024/2025 and sustaining ~25-30% share in mature asthma/COPD markets despite generics.
Strong brand loyalty and recognition as a cost‑effective standard of care keep prescribing high, so marketing spend is minimal and net margins stay robust.
Free cash flow from Symbicort is being harvested to fund Stars like Tezspire (2025 revenue: $3.1 billion), supporting R&D and commercial expansion.
Soliris (Eculizumab)
Soliris (eculizumab), once AstraZeneca's star, is a fading Cash Cow: it generated $2.59 billion in 2025, but sales fell 26% in the final quarter as patients migrated to Ultomiris.
It still delivers high-margin cash in select markets and legacy indications with essentially zero R&D spend; AZ is milking the asset ahead of biosimilar erosion.
- 2025 sales $2.59B; Q4 -26%
- High margins, no incremental R&D
- Value concentrated in older indications/markets
- Facing biosimilar and Ultomiris substitution pressure
Brilinta (Ticagrelor)
Brilinta (ticagrelor) produced $1.33 billion in 2024/2025 sales, acting as AstraZeneca's cash cow in the antiplatelet segment with low growth but predictable hospital demand.
Pressure from generic clopidogrel and price-sensitive markets limits expansion, yet entrenched guideline use keeps steady margins to fund AZ's shift into high-growth cardiometabolic R&D.
- 2024/25 sales: $1.33B
- Role: steady hospital revenue, low growth
- Threat: cheaper generics; Opportunity: funding R&D
AZ's $17.3B cash-cow core funds $13B+ R&D - Tagrisso, Lynparza lead; Soliris slides
Tagrisso $7.25B (2025, +10%); Lynparza $3.28B (+6%); Symbicort $2.88B; Soliris $2.59B (2025, Q4 -26%); Brilinta $1.33B - all high-margin, low-growth cash cows funding AZ's R&D ($13B+).
| Product | 2025 Sales | Growth |
|---|---|---|
| Tagrisso | $7.25B | +10% |
| Lynparza | $3.28B | +6% |
| Symbicort | $2.88B | ~0% |
| Soliris | $2.59B | -26% Q4 |
| Brilinta | $1.33B | ~0% |
Delivered as Shown
AstraZeneca BCG Matrix
The file you're previewing on this page is the final AstraZeneca BCG Matrix you'll receive after purchase-no watermarks, no placeholders, just a fully formatted, presentation-ready strategic analysis tailored for pharma portfolio decisions.
This preview is the exact same document you'll download post-purchase, built with market-backed metrics and clear visuals so you can immediately use it in board decks, investor updates, or internal strategy sessions.
Upon purchase you'll get the full editable file delivered to your inbox-no surprises, no revisions required-ready for printing, customization, or sharing with stakeholders.
What you see here is the real AstraZeneca BCG Matrix report crafted by strategy experts, designed for clarity and immediate application in product lifecycle and resource-allocation planning.
